AMLX Amylyx Pharmaceuticals

Watchlist

3.600
+0.040+1.12%

Trading Jan 24 13:14 ET

308.48MMarket Cap-0.94P/E (TTM)

About Amylyx Pharmaceuticals Company

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Company Profile

SymbolAMLX

Company NameAmylyx Pharmaceuticals

Listing DateJan 7, 2022

Issue Price19.00

Founded2013

MarketNASDAQ

Employees384

Fiscal Year Ends12-31

Address43 Thorndike Street

CityCambridge

ProvinceMassachusetts

CountryUnited States of America

Zip Code02141

Phone1-617-682-0917

Websitehttp://www.amylyx.com

Company Executives

Name
Position
Salary

Joshua Cohen
Co-Chief Executive Officer and Director
7.42M

Justin Klee
Co-Chief Executive Officer and Director
7.42M

Gina M. Mazzariello
Chief Legal Officer and General Counsel
3.01M

Dr. Camille L. Bedrosian,M.D.
Chief Medical Officer
2.37M

James M. Frates
Chief Financial Officer and Principal Accounting Officer
3.51M

Dr. George Mclean Milne, Jr,PhD
Chairman of the Board
385.07K

Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D.
Director
--

Paul Fonteyne, M.S.
Independent Director
342.12K

Karen Firestone
Independent Director
681.15K

Daphne E. Quimi
Independent Director
348.59K

AMLX Amylyx Pharmaceuticals

About Amylyx Pharmaceuticals Company

Company Profile

Company Executives

Trending Stocks